Clinical Trials on Niemann-Pick Disease, Type A in Czechia

Total 1115 results

Sanofi

Completed

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States, Chile, Czech Republic, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden
European Organisation for Research and Treatment...

Unknown

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Leukemia

Belgium, Netherlands, Czech Republic, Hungary, Italy, Macedonia, The Former Yugoslav Republic of, Portugal
Eli Lilly and Company

Completed

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes (AWARD-6)

Type 2 Diabetes

United States, Germany, Puerto Rico, Hungary, Spain, Poland, Mexico, Romania, Slovakia, Czech Republic
European LeukemiaNet

Completed

European Stop Tyrosine Kinase Inhibitor Study (EURO-SKI)

Chronic Myeloid Leukemia

France, Denmark, Norway, Sweden, Czechia, Portugal, Germany, Netherlands, Finland, Greece
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus (EDITION JUNIOR)

Type 1 Diabetes Mellitus

France, Czechia, Chile, Israel, Spain, Hungary, Mexico, Serbia, Japan, Canada, Brazil, Sweden, Denmark, Argentina, United States, Bulgaria, Germany, Italy, Latvia, North Macedonia, Poland, Romania, Russian Federation, United Kingdom
Foresee Pharmaceuticals Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Prostatic Neoplasms

Czechia, United States, Poland, Austria, Germany, Lithuania, Slovakia, Taiwan
Curis, Inc.

Recruiting

A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Relapsed Primary Central Nervous System Lymphoma | Refractory Hematologic Malignancy | Relapsed Hematologic Malignancy | Refractory Primary Central Nervous System Lymphoma

United States, Spain, France, Czechia, Israel, Italy, Poland
Eli Lilly and Company

Completed

An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin (SWING)

Diabetes Mellitus, Type 2

Hungary, Greece, Germany, Turkey, Romania, Czech Republic, Slovakia, Austria, Poland
AstraZeneca

Completed

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico, Mexico, Russian Federation, Romania, Poland, Czech Republic, United Kingdom
Takeda

Completed

Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.

Type 2 Diabetes

United States, Poland, United Kingdom, Germany, South Africa, Finland, Estonia, Slovakia, Czech Republic
Novartis Pharmaceuticals

Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Spain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Eisai Inc.

Completed

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Metastatic Renal Cell Carcinoma

United States, Poland, United Kingdom, Spain, Czechia
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Diabetes Mellitus, Type 2

United States, Romania, Canada, Russian Federation, Czech Republic, Slovakia, Mexico
Lexicon Pharmaceuticals
Sanofi

Completed

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone (inTandem3)

Type 1 Diabetes Mellitus (T1DM) | High Level of Sugar (Glucose) in the Blood

United States, Australia, Spain, Belgium, Argentina, Bulgaria, Canada, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Slovakia, South Africa, United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom
Sanofi

Completed

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Type 2 Diabetes Mellitus

Spain, United States, Canada, Czech Republic, France, Germany, Poland, Romania, Russian Federation, Ukraine
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Genzyme, a Sanofi Company

Completed

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET)

Glycogen Storage Disease Type II;Pompe's Disease

Czechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
Novo Nordisk A/S

Recruiting

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Hungary, Serbia, Spain, China, Australia, Finland, United Kingdom, Italy, Denmark, Canada, Taiwan, Poland, Germany, Sweden, South Africa, India, Argentina, Brazil, Bulgaria, Japan, Mexico, Turkey, Greece, Colomb... and more
AstraZeneca

Completed

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings (DISCOVER)

Type 2 Diabetes Mellitus

Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, South Africa, Spain, Turkey, China, Netherlands, Argentina, Austria, Czechia, United Arab Emirates, Taiwan, India, Egypt, Saudi Arabia, Lebanon, Indonesia, Col... and more
Novartis Pharmaceuticals

Withdrawn

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Basal Cell Carcinoma

Greece, Switzerland, Germany, United Kingdom, Belgium, Canada, Czechia, Finland, Italy, Spain
ChemoCentryx

Completed

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

Type 2 Diabetes Mellitus | Diabetic Nephropathy

Poland, United Kingdom, Germany, Belgium, Hungary, Czechia
Basilea Pharmaceutica

Completed

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)

Urothelial Carcinoma

United Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
Mannkind Corporation

Completed

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

Diabetes, Type 2 | Diabetes, Type 1

United States, Spain, Canada, Russian Federation, Czech Republic, Poland, Ukraine, United Kingdom
AstraZeneca

Terminated

GALLANT 22 Tesaglitazar vs. Placebo

Type 2 Diabetes

Czech Republic, France, Poland, Philippines, Estonia, Latvia, Lithuania, Norway, Hungary, Slovakia, Greece, Sweden, Australia, Former Serbia and Montenegro
Seagen Inc.
Bristol-Myers Squibb

Active, not recruiting

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, Australia, Czechia, Italy, Spain, Poland
Centocor, Inc.

Completed

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

France, United Kingdom, Netherlands, Czech Republic
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Disease, Hodgkin

United States, United Kingdom, France, Romania, Poland, Italy, Bulgaria, Hungary, Russian Federation, Czechia, Spain, Germany, Serbia
Calliditas Therapeutics AB

Completed

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

Australia, United States, Germany, Poland, Canada, Czech Republic
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy (EDITION III)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Terminated

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Diabetes Mellitus and Heart Failure

United States, Belgium, Austria, Croatia, Czechia, Netherlands, Canada, Korea, Republic of, Taiwan, Hungary, United Kingdom, Italy, Bulgaria, Germany, Argentina, Ireland, Norway, Spain, Denmark, Singapore, South Africa, Mexico, Poland, Puerto Rico
MacroGenics
Eli Lilly and Company

Terminated

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States, Israel, United Kingdom, Poland, France, Germany, Belgium, Finland, India, Ukraine, Spain, Czechia, Italy, Mexico, Netherlands, Romania
PregLem SA

Completed

PGL4001 Versus Placebo in Uterine Myomas (PEARLI)

Uterine Myomas

Czech Republic, Hungary, India, Romania, Russian Federation, Ukraine
AstraZeneca

Completed

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation, Romania, Poland, Czech Republic, Puerto Rico, Hungary
Novo Nordisk A/S

Completed

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Russian Federation, Serbia, Turkey, Algeria, Czechia
ALX Oncology Inc.
Eli Lilly and Company

Recruiting

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Spain, France, Korea, Republic of, Taiwan, United Kingdom, Japan, Singapore, Belgium, Czechia, Italy
Phenomix
Forest Laboratories

Terminated

Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

Type 2 Diabetes Mellitus

United States, Argentina, Chile, Czech Republic, India, Peru, Poland
Tracon Pharmaceuticals Inc.

Terminated

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Hungary, Czechia, United Kingdom
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)

Type 2 Diabetes

United States, Puerto Rico, Spain, Germany, Argentina, Brazil, Turkey, Hungary, Italy, Russian Federation, Slovakia, Belgium, Czechia, Greece, Mexico, Romania
Pfizer

Completed

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Multiple Myeloma

United States, Germany, Czech Republic
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)

Diabetes | Type 2 Diabetes

United States, China, Germany, Mexico, Brazil, Canada, Japan, Korea, Republic of, Puerto Rico, Czechia, Greece
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

Type 2 Diabetes Mellitus

United States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
Sanofi

Terminated

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)

Sleep Initiation and Maintenance Disorders

United States, Canada, Brazil, Russian Federation, Australia, Germany, Italy, Spain, Turkey, India, Malaysia, Singapore, Belgium, Czech Republic, Mexico, Argentina, Austria, Colombia, Chile, South Africa, United Kingdom, Hong Kong
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Hodgkin's Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Canada, United States, Brazil, Czechia, France, Italy, Poland, Russian Federation, South Africa, Turkey, Ukraine
Provention Bio, a Sanofi Company

Active, not recruiting

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Diabetes Mellitus, Type 1

United States, Belgium, Canada, Czechia, France, Germany, Poland, United Kingdom
Takeda

Terminated

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Narcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)

China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Type II Diabetes Mellitus

United States, Russian Federation, Czech Republic, Hungary, Netherlands
Amgen

Active, not recruiting

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Obesity | Overweight | Type 2 Diabetes Mellitus

United States, Czechia, Taiwan, Canada, Japan, Korea, Republic of, Germany, Hungary, Australia, Hong Kong, Spain, Poland

Clinical Trials on Niemann-Pick Disease, Type A in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations